Abstract: The disclosure relates to defined solutions for organ (heart, liver, kidney, etc,) vascular composite allografts or autografts (VCA: hand, limb, face, etc.) or tissue (peripheral nerves, spinal cord, skin) storage that preserve the electrophysiological functions of axons contained therein. The disclosure also concerns the use of isolated peripheral nerve segments and solid organs preserved in the defined solutions in autograft or allograft transplantation procedures, as well as the use of isolated peripheral nerve segments and solid organs preserved in the defined solutions in autograft/allograft transplantation procedures in combination with the peripheral nerve repair techniques of neurorrhaphy and axonal fusion primarily using polyethylene glycol known as PEG-fusion.

Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.

Abstract: A computer-implemented method of training a neural network to improve a characteristic of a protein comprises collecting a set of amino acid sequences from a database, compiling each amino acid sequence into a three-dimensional crystallographic structure of a folded protein, training a neural network with a subset of the three-dimensional crystallographic structures, identifying, with the neural network, a candidate residue to mutate in a target protein, and identifying, with the neural network, a predicted amino acid residue to substitute for the candidate residue, to produce a mutated protein, wherein the mutated protein demonstrates an improvement in a characteristic over the target protein. A system for improving a characteristic of a protein is also described. Improved blue fluorescent proteins generated using the system are also described.

Abstract: Provided herein are methods and compositions for the treatment of cancer by modulating the microbiome to enhance the efficacy of immune checkpoint blockade. The microbiome may be modulated by the administration of butyrate and/or butyrate-producing bacteria. Also provided herein are methods of determining a response to an immune checkpoint inhibitor by identifying if a subject has a favorable microbial profile.

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

Abstract: Neural interfaces with the peripheral nervous system have been developed to provide a direct communication pathway between peripheral nerves and prosthetic limbs. Described herein is a method of making a microchannel integrated neural interface device comprising a plurality of hollow cylindrical electrodes in a PDMS scaffold, which can control the reinnervated muscles and interpret neurological signals. The acquired bioelectrical signals can be used for the interpretation of mind and create a neural map.

Abstract: Duchenne muscular dystrophy (DMD) is a fatal muscle disease caused by the lack of dystrophin, which maintains muscle membrane integrity. Provided herein are methods of using adenine base editor (ABE) to modify splice sites of the dystrophin gene, causing skipping or refraining of common DMD exon deletion mutations, restoring dystrophin expression. Also provided herein are methods of using prime editing to reframe the dystrophin open reading frame and restore dystrophin expression.

Abstract: A method and system for downloading the information stored on an IoT device is presented. All in-system programming pins are identified by inspection with visible light or using a computed tomography scan of the device using X-radiation. Based on this inspection, a 3D fixture is fabricated that accommodates spring-loaded pin connectors for contacting the identified in-system programming taps on the main printed circuit board of the device. The 3D test jig, in conjunction with a logic analyzer, can extract data from the internet of things (IoT) device.

Abstract: 3D MRI images of the brain may be created and acquired. After administration of contrast, brain lesions and other abnormalities may be identified and isolated from the 3D MRI images, with each lesion serving as a region of interest (ROI). 3D region of contrast enhancement images may be created from segmented 3D MRI images and different regions of contrast enhancement of the brain lesion may be depicted. Saved regions of contrast enhancement may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D region of contrast enhancement images may be used to create 3D printed models of the isolated region of contrast enhancement. Analysis of the 3D brain region of contrast enhancement images and the 3D printed region of contrast enhancement models may enable a more efficient and accurate way of determining brain lesion risk factors and effective treatment regimens.

Abstract: In one aspect, compositions and wound dressings are described herein. In some embodiments, a composition or wound dressing described herein comprises a mesh formed from a plurality of biodegradable polymer fibers; a first active agent dispersed in the biodegradable polymer fibers; a plurality of biodegradable polymer particles disposed in the mesh; and a second active agent dispersed in the biodegradable polymer particles. The particles can be disposed within the interiors of the fibers of the mesh or between the fibers of the mesh. In another aspect, a composition or wound dressing described herein comprises a first perforated mesh formed from a first plurality of biodegradable polymer fibers; and a second perforated mesh formed from a second plurality of biodegradable polymer fibers, wherein the second perforated mesh is disposed on the first perforated mesh in a stacked configuration and the first and second perforated meshes have different degrees of perforation.

Abstract: A device for ion chromatography comprises a tube with an inlet opening and an outlet opening and an inner diameter from about 40 microns to about 10 microns. There is an aperture through one side of the tube into a lumen of the tube. At least a portion of the inner surface of the tube has a first charge. An ion exchange barrier covers the aperture on an outside surface of the tube. The inner surface of the tube, from the inlet opening to the aperture, is coated with ion exchange particles having a diameter ranging from about 30 nm to about 200 nm. The ion exchange particles have a second charge opposite the first charge. The inner surface of the tube, from the outlet opening to the aperture, is not coated with ion exchange particles.

Abstract: An electrical device, comprising a softening polymer layer, an electrode layer on a surface of the softening polymer layer and a cover polymer layer on the surface of the softening polymer layer. An opening in the polymer cover layer is filled with a reflowed solder, one end of the reflowed solder, located inside the opening, contacts a contact pad site portion of the electrode layer, and another end of the reflowed solder contacts an electrical connector electrode of the device.

Abstract: Apparatus and methods for imaging a region of a subject comprising an artifact. In certain embodiments, the apparatus and methods utilize computed tomography (CT) scans obtained at two different angles to image a region posterior to an artifact.

Abstract: A cystoscopy system with intracranial electrodes operable to be disposed in a hippocampus region of a brain and configured to record electrical signals that include biomarkers related to memory encoding, a neurostimulator configured to stimulate a posterior cingulate cortex (PCC) of the brain, a NARXNN plant model, and a controller configured to receive the electrical signals and modulate an input/output (I/O) relationship between the biomarkers and electrical stimuli applied to a posterior cingulate cortex (PCC) of the brain by controlling the neurostimulator to stimulate the PCC based on the I/O relationship to achieve a desired level of the biomarkers.

Abstract: Methods, apparatuses, systems, and implementations for creating 3-dimensional (3D) representations exhibiting geometric and surface characteristics of brain lesions are disclosed. 2D and/or 3D MRI images of the brain may be acquired. Brain lesions and other abnormalities may be identified and isolated with each lesion serving as a region of interest (ROI). Saved ROI may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D brain lesion images may be used to create 3D printed models of the isolated brain lesions using 3D printing technology. Analysis of the 3D brain lesion images and the 3D printed brain lesion models may enable a more efficient and accurate way of determining brain lesion etiologies.

Abstract: Provided herein is a machine learning model to reconstitute T cell and B cell selections, and methods of use thereof. The methods provided herein include methods of prediction of the risk of developing an autoimmune disease or disorder, the risk of developing alloimmunity from organ or cellular transplant, the risk of developing graft-versus-host disease (GvHD) from organ or cellular transplant, the risk of developing alloimmunity from an adoptive T cell therapy, the risk of developing alloimmunity from a chimeric antigen receptor (CAR)-T cell therapy, and methods of prediction of the safety of an antibody drug in a subject. Also provided herein is a method of classifying T cell receptor p (TCRp) gene, and methods of use thereof. The methods provided include methods of determining an organ donor/organ recipient compatibility, methods of predicting graft versus host disease (GvHD) in a recipient, acute GvHD (aGvHD), chronic GvHD (cGvHD) and cancer relapse in a subject.

Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.

Abstract: The inventors have used a differential nuclear staining (DNS) assay to discover compounds with cytotoxic activity against the CEM cell line that has been determined to be highly sensitive to a variety of anti-cancer compounds. Compounds were synthesized based on a pyrazole backbone structure. Several newly synthesized compounds have been tested to identify the compounds with highest activity. One compound identified is the SSK-3 compound which has been tested on cancer cell lines and determined that it induced apoptosis via phosphatidylserine membrane exposure and activation of caspase 3 in the CEM lymphoma cell line.

Abstract: Provided herein are BAFF-R antibodies as well as compositions and methods of making and using the same. The antibodies provided herein are, inter alia, useful for the treatment of cancer and autoimmune diseases.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.